Eli Lilly and Co (LLY) Stock News

Eli Lilly (LLY) has been trending on Zacks.com with shares returning +4.2% over the past month, outperforming the S&P 500's +1.3%. The company shows strong fundamentals with expected earnings growth of +40% for the current quarter and +51.3% for the fiscal year. However, the stock carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (Grade D) compared to peers, suggesting it may perform in line with the broader market in the near term.

A securities class action lawsuit has been filed against XTI Aerospace, Inc. for allegedly making materially false and misleading statements during April 15 - August 17, 2026. The lawsuit claims senior executives engaged in undisclosed activities that affected disclosure controls and prevented timely earnings report filings. Investors who purchased securities during this period may be eligible for compensation. The deadline to serve as lead plaintiff is October 27, 2026.

Rosen Law Firm is notifying investors about securities class action lawsuits, including one against Hyliion Holdings Corp. for allegedly making false statements about its VFG Holdings partnership and commercial pipeline credibility. The firm is seeking a lead plaintiff by October 27, 2026, and encourages affected investors to join the litigation.

Novo's COMPETE SWITCH CV study found that patients who escalated their Ozempic dose to 2 mg had a 6% lower observed risk of major adverse cardiovascular events (MACE) compared to those who switched to Eli Lilly's Mounjaro. However, the study shows association rather than causation and did not evaluate safety outcomes.

Rosen Law Firm has issued multiple securities class action deadline alerts for investors. GoDaddy Inc. faces allegations of making false statements about customer growth strategy and average order size, with an October 20, 2026 lead plaintiff deadline. The firm is also handling class actions for FuelCell Energy Inc. and The Simply Good Foods Company with similar investor protection deadlines.

Rosen Law Firm reminds investors who purchased Innventure, Inc. (NASDAQ: INV) securities between November 17, 2025 and August 13, 2026 of the October 27, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Innventure made materially false statements regarding Accelsius Holdings LLC's transformative deal with DarkNX, which allegedly lacked evidence of execution, resulting in overstated revenue and cash flow targets for 2026.

L'Oréal has successfully priced a €2 billion bond offering across three tranches with maturities of 2, 3, and 7 years. The bonds are expected to be rated AA (Stable) by S&P and Aa1 (Stable) by Moody's, and will be admitted to trading on Euronext Paris on September 30, 2026. The net proceeds will be used for general corporate purposes.

Eli Lilly closed at $1,164.89, up 1.04% but underperforming the S&P 500's 1.49% gain. The stock declined 8.16% over the past month, trailing the broader market. Analysts expect strong earnings growth of 36.18% YoY with revenue projected at $22.08 billion (+25.46%), but the company trades at a premium valuation with a Forward P/E of 31.94 versus the industry average of 15.87. Eli Lilly holds a Zacks Rank #3 (Hold) rating.

A securities class action lawsuit has been filed against UWM Holdings Corporation for allegedly making materially false statements regarding its mortgage servicing rights hedging strategy. The lawsuit claims the company deviated from its traditional non-hedging approach, over-hedged in anticipation of the Two Harbors transaction, and created excess hedging risk while making misleading positive statements about its business. Investors who purchased securities between March 9, 2026 and August 5, 2026 may be eligible for compensation. The lead plaintiff deadline is October 13, 2026.

Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales and continues driving growth. The company's oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs, while newer therapies grew 121% in Q2, diversifying revenue beyond GLP-1. However, the stock trades at a premium 26.3x forward earnings amid intensifying competition from Novo Nordisk and smaller biotechs in the oral GLP-1 market. Analysts recommend existing investors hold while new investors consider accumulating on market corrections.

Rosen Law Firm announces a September 22, 2026 deadline for investors to join a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges the company made materially false statements regarding its handpiece unit sales and revenues, claiming an undisclosed discount program artificially inflated sales figures, created excess inventory of over 10,000 units, and that the company could not achieve its 2025 guidance.

Eli Lilly (LLY) rose 1.99% to $1,137.86 in the latest session, outperforming the S&P 500's 0.48% decline. However, shares have depreciated 5.46% over the past month. The company is expected to report earnings on October 29, 2026, with projected EPS of $9.56 (up 36.18% YoY) and revenue of $22.08 billion (up 25.46% YoY). LLY currently holds a Zacks Rank #3 (Hold) with a Forward P/E of 30.92, trading at a premium to its industry average.

Rosen Law Firm has filed securities class action lawsuits against Blaize Holdings, Hyliion Holdings, and Primoris Services Corporation, alleging false statements and improper revenue recognition. Investors who purchased securities during specified class periods are encouraged to join the litigation before upcoming deadlines, with the lead plaintiff deadline for Blaize set for October 5, 2026.

Rosen Law Firm reminds investors in Cogent Communications Holdings, Inc. (NASDAQ: CCOI) who purchased stock between February 29, 2024 and May 1, 2026 of the September 21, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding optical wavelength backlog, customer demand, revenue targets, dividend sustainability, and undisclosed risks related to insider stock pledging activities.

The article examines the reliability of Wall Street analyst recommendations versus the Zacks Rank system. While Eli Lilly has a strong average brokerage recommendation (ABR) of 1.45 (Buy-equivalent), the article cautions that brokerage analysts often exhibit positive bias due to vested interests. In contrast, the Zacks Rank, which is based on earnings estimate revisions, has demonstrated superior predictive power for near-term stock price movements. Lilly's unchanged consensus estimate resulted in a Zacks Rank #3 (Hold), suggesting caution despite the bullish ABR.

Rosen Law Firm has filed a class action lawsuit against Innventure, Inc. (NASDAQ: INV) on behalf of investors who purchased securities between November 17, 2025 and August 13, 2026. The lawsuit alleges that defendants made materially false and misleading statements regarding Accelsius Holdings LLC's transformative deal with DarkNX, which allegedly was unlikely to materialize, and that revenue and cash flow targets for 2026 were overstated. Investors must move the court by October 27, 2026 to serve as lead plaintiff.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Alibaba Group Holding Limited. The lawsuit alleges that Alibaba made false and misleading statements regarding its control by the Chinese Ministry of Industry and Information Technology (MIIT), which would classify it as a Chinese military company under the National Defense Authorization Act, and failed to disclose ongoing distillation attacks against third-party AI models. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is notifying investors in Avis Budget Group (CAR) and Park Ha Biological Technology (PHH, BYAH) about ongoing securities class action lawsuits. The Avis lawsuit alleges that Pentwater Capital Management LP and its CEO orchestrated a market manipulation scheme involving aggressive stock purchases that triggered a short squeeze, artificially inflating stock prices. Investors with losses exceeding $100,000 are encouraged to join the class action before the September 29, 2026 deadline.

Rosen Law Firm is notifying investors of securities class action lawsuits against Blaize Holdings, GoDaddy Inc., and Rackspace Technology. The lawsuits allege false statements, improper revenue recognition, and misleading disclosures. Investors have until specified deadlines to join as lead plaintiffs or class members.

Eli Lilly announced its 10th acquisition of 2026, agreeing to acquire Merida Biosciences for up to $2.875 billion to strengthen its immunology pipeline. The company is strategically diversifying its portfolio across oncology, immunology, neuroscience, and vaccines to reduce reliance on GLP-1 medicines (Mounjaro and Zepbound), which currently account for 65% of revenues. Other major pharma companies including Merck, Gilead Sciences, and AbbVie are also pursuing significant M&A deals to expand pipelines and enter new therapeutic areas.

Rosen Law Firm is reminding investors who purchased Datavault AI Inc. securities between September 4, 2024 and October 30, 2025 of an important October 5, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding corporate partnerships, overstated trading activity on the Datavault Platform, and failed to disclose connections with a convicted felon, causing reputational harm.

The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in high-risk adults with type 2 diabetes. In a 13,299-patient study, Mounjaro showed an 8% lower MACE-3 rate than Trulicity, meeting non-inferiority objectives. With $18.6B in first-half 2026 sales, this expanded indication could drive further growth and narrow the competitive gap with Novo Nordisk's Ozempic.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Alarum Technologies Ltd. (ALAR) for allegedly making false statements about its business. The lawsuit claims that Alarum's subsidiary NetNut was engaging in illegal activity by linking customer home internet devices into another network without consent, enabling cybercriminals to conceal their locations. The firm alleges these undisclosed activities materially heightened legal exposure and threatened business prospects. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm has filed class action lawsuits against Hyliion Holdings Corp. (HYLN) for alleged false statements regarding a business deal with a recently formed entity lacking actual operations, and potential insider trading by executives. A separate class action has been filed against Insulet Corporation (PODD) with an August 31, 2026 deadline for lead plaintiff motions. Both lawsuits allege material misstatements that caused investor losses.

Rosen Law Firm is alerting investors in Microvast Holdings (MVST) about a securities class action lawsuit with a September 21, 2026 lead plaintiff deadline. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion, causing investor losses.

A securities class action lawsuit has been filed against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group stock. The defendants, holding approximately 51% economic interest in Avis, allegedly engaged in aggressive stock purchases during February 2025 to April 2026 that triggered a short squeeze, artificially inflating the stock price and benefiting their holdings. Investors who purchased Avis securities during this period may be eligible for compensation, with a September 29, 2026 deadline to serve as lead plaintiff.

Rosen Law Firm announces securities class action lawsuits against multiple companies. Verra Mobility is accused of making false statements about its relationship with Avis Budget Group and concealing material adverse facts. Hub Group and Alarum Technologies are also subjects of investigations for potential securities violations. Investors are urged to secure counsel before upcoming deadlines.

Rosen Law Firm reminds investors in Futu Holdings Limited of the August 25, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Futu made materially false statements regarding compliance with China Securities Regulatory Commission requirements, failed to disclose regulatory risks, and overstated financial results. Investors who purchased securities between May 24, 2023 and May 27, 2026 may be eligible for compensation.

A class action lawsuit has been filed against Citadel Securities LLC and Virtu Americas LLC on behalf of Genius Group Limited investors. The defendants are accused of engaging in 'spoofing'—submitting and canceling buy/sell orders without intent to execute them—to manipulate Genius stock prices and mislead market participants. The lead plaintiff deadline is August 28, 2026. Investors who purchased or sold Genius securities between April 12, 2022 and May 30, 2025 may be eligible for compensation.

Rosen Law Firm reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors who purchased stock between April 16, 2025 and May 4, 2026 of the August 3, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when defendants knew of significant viability problems that would negatively impact the business.